Lower Sales of Pharmaceutical Intermediates and Functional Chemicals Due to Weaker Overseas Customer Demand
First written in FY2017-Q2. 6 of 16 entries say "Mitigated", first in FY2018-Q1. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1MitigatedAnnual report
「Sales of dehydration condensation agents for pharmaceutical intermediates declined in Japan due to weak demand, while overseas sales increased.」
Sales of pharmaceutical intermediates for overseas markets increased, improving from the previous sales decline caused by weak demand from overseas customers. Domestic sales, however, declined. - FY2024-Q1WorsenedAnnual report
「For pharmaceutical intermediates, full-year sales of the dehydrative condensing agent for medical applications are expected to exceed the prior fiscal year, but sales in Q1 were below the year-earlier period.」
Although dehydration condensation agents for medical applications are expected to exceed the previous fiscal year’s level for the full year, sales fell below the previous year’s level in the first quarter, indicating short-term weakness in demand and sales, including overseas. - FY2023-Q2WorsenedAnnual report
「For pharmaceutical intermediates, revenue for Japan increased, led by medical-use dehydrating condensation agents. Although sales increased for some overseas products, sales declined for others, resulting in lower total revenue than in the same period of the previous year.」
Sales of pharmaceutical intermediates for overseas markets varied by product, and total sales fell below the previous year’s level. - FY2023-Q1WorsenedAnnual report
「Although sales of some dehydration condensation agents for medical applications increased, total sales of pharmaceutical intermediates fell below the previous year’s level.」
Although sales of some dehydration condensation agents for medical applications increased, total sales of pharmaceutical intermediates fell below the previous year’s level. - FY2021AdvancedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the previous period as the company focused on manufacturing and selling medical-use dehydrating condensation agents with quality and technological advantages, proactively responded to customer requirements, and increased sales in both Japan and overseas markets.」
Sales increased in both domestic and overseas markets, supported by a focus on dehydration condensation agents for medical applications and responses to customer requirements, improving from the previous sales decline caused by weak overseas demand. - FY2021-Q3MitigatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the same period of the previous year as the company focused on manufacturing and selling medical-use dehydrating condensation agents with quality and technological advantages in both Japan and overseas markets, and proactively responded to customer requirements, increasing sales.」
Sales of pharmaceutical intermediates, including products for overseas markets, increased, improving from the previous sales decline caused by weak overseas demand. - FY2021-Q1RestatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the same period of the previous year as sales increased in both Japan and overseas markets in response to customer requirements.」
For pharmaceutical intermediates, for which weak overseas demand had previously been indicated, increased sales and sales above the previous year’s level are reported in both domestic and overseas markets. - FY2020-Q3MitigatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the same period of the previous year as sales of core products increased on expanding demand from pharmaceutical customers, although the failure to win orders for contract-manufactured products had an impact.」
Although orders for contract-manufactured products remained unsecured, sales of pharmaceutical intermediates improved to above the previous year’s level due to increased demand from pharmaceutical customers. - FY2020-Q1WorsenedAnnual report
「Pharmaceutical intermediates posted lower revenue than in the same period of the previous year overall, although orders increased for some products and were not won for others.」
Although orders increased for some products, orders could not be secured for others, and total sales of pharmaceutical intermediates fell below the previous year’s level. - FY2019-Q3RestatedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue than in the same period of the previous year, although overseas revenue was slightly lower, as the company won orders in Japan and increased sales.」
Although overseas sales were slightly below the previous year’s level, total sales exceeded the previous year’s level due to secured domestic orders and increased domestic sales. - FY2019-Q2WorsenedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue than in the same period of the previous year, although overseas revenue was slightly lower, as the company won orders in Japan.」
Although increased overseas orders were reported in the previous quarter, overseas sales in the current quarter were slightly below the previous year’s level. - FY2019-Q1MitigatedAnnual report
「For pharmaceutical intermediates and functional chemicals, orders for key overseas products were received from the second quarter onward, while some products won orders in Japan during the current quarter, increasing revenue.」
The description changed from the previous sales decline due to weaker overseas demand to an explanation that sales increased, including through securing domestic orders. - FY2018-Q3MitigatedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue than in the same period of the previous year overall, despite variations by product, partly due to an increase in overseas orders.」
The situation has improved from the previous sales decline due to weaker overseas demand to sales above the previous year’s level, supported by increased overseas orders. - FY2018-Q1MitigatedAnnual report
「Pharmaceutical intermediates and functional chemicals secured overseas orders and increased sales, but」
The situation changed from lower sales due to weaker demand from overseas customers in the previous fiscal year to increased overseas orders and sales growth. - FY2017-Q3RestatedAnnual report
「Sales of pharmaceutical intermediates and functional chemicals declined in overseas markets due to lower customer production and competition from other companies.」
Lower sales in overseas markets due to lower customer production and competition from other companies continue to be reported. - FY2017-Q2First statedAnnual report
「Sales of pharmaceutical intermediates and functional chemicals declined overseas because of lower customer demand and competition from other companies.」
Lower overseas customer demand was first identified separately as a factor behind the decline in sales of pharmaceutical intermediates and functional chemicals.